4 Reasons Arrowhead Pharmaceuticals Could Be the Next Biotech Buyout

Danish pharmaceutical giant, Novo Nordisk (NYSE: NVO) made a lot of headlines recently with a big buyout offer for Dicerna Pharmaceuticals (NASDAQ: DRNA). Novo Nordisk offered Dicerna shareholders a great big 80% premium, leading investors to wonder which biotech stock might be next. 

For good reasons, Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a prime candidate for the next big biotech buyout. Here are four of the most important ones. 

Image source: Getty Images.

Continue reading

Source Fool.com